EASL 2015: Hepatitis C Treatment Could Cut HCV Transmission Among UK Gay Men in Half

Access to more effective hepatitis C treatment could reduce new infections among men who have sex with men in the United Kingdom by half over the next decade, according to a mathematical modeling study presented at the European Association for the Study of the Liver (EASL) International Liver Congress in Vienna in April.

alt

Read more:

EASL 2015: Reinfection after HCV Cure - Long-term Support Needed for People Who Have Injected Drugs

Reinfection rates after a hepatitis C cure among people who inject drugs, as well as past drug users, are relatively low, according to findings from studies from Norway and Canada presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna in April. The findings suggest that current and former injection drug users who have been cured of hepatitis C require ongoing support to remain free of HCV, but also indicate that fears of a high rate of reinfection should not be used as a reason to withhold hepatitis C treatment from people who inject drugs.

alt

Read more:

EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England

Reducing the duration of direct-acting antiviral therapy for hepatitis C will make treatment for prisoners in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people who inject drugs, Natasha Martin from the University of California San Diego reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

EASL 2015: Using Interferon with Hepatitis B Antivirals Raises Likelihood of HBsAg Loss

Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate was still just 9%, according to a study presented at the recent European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Other researchers reported that adding 48 weeks of interferon to nucleoside/nucleotide therapy increased the rate of HBsAg loss to about the same level, and switching to interferon may be effective for selected patients.

alt

Read more:

DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation

Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.

alt

Read more:

More Articles...